Brokerages Set Keryx Biopharmaceuticals, Inc. (KERX) PT at $7.28
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has been assigned an average recommendation of “Hold” from the nine research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $7.28.
Several research firms have weighed in on KERX. BidaskClub upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Maxim Group reiterated a “buy” rating and issued a $9.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Thursday, July 20th. ValuEngine lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. Cowen and Company reiterated a “market perform” rating on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Finally, Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 14th.
Shares of Keryx Biopharmaceuticals (KERX) traded up 0.62% during mid-day trading on Thursday, hitting $6.50. 996,161 shares of the stock traded hands. The stock has a 50-day moving average of $7.17 and a 200-day moving average of $6.77. The company’s market cap is $771.88 million. Keryx Biopharmaceuticals has a 52 week low of $4.11 and a 52 week high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.60). The firm had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.51 million. Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The firm’s revenue was up 62.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.42) EPS. Analysts anticipate that Keryx Biopharmaceuticals will post ($1.23) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Brokerages Set Keryx Biopharmaceuticals, Inc. (KERX) PT at $7.28” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/22/brokerages-set-keryx-biopharmaceuticals-inc-kerx-pt-at-7-28.html.
Institutional investors have recently added to or reduced their stakes in the business. Westpac Banking Corp acquired a new position in Keryx Biopharmaceuticals in the 2nd quarter valued at approximately $390,000. Stifel Financial Corp increased its stake in shares of Keryx Biopharmaceuticals by 11.5% during the 1st quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 3,478 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Keryx Biopharmaceuticals by 1.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 441,106 shares of the biopharmaceutical company’s stock worth $3,190,000 after purchasing an additional 4,388 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Keryx Biopharmaceuticals during the 2nd quarter worth $648,000. Finally, Parametric Portfolio Associates LLC increased its stake in shares of Keryx Biopharmaceuticals by 60.1% during the 1st quarter. Parametric Portfolio Associates LLC now owns 192,982 shares of the biopharmaceutical company’s stock worth $1,189,000 after purchasing an additional 72,436 shares during the last quarter. Hedge funds and other institutional investors own 65.19% of the company’s stock.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.